Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
2.020
+0.090 (4.66%)
At close: Jul 8, 2025, 4:00 PM
2.010
-0.010 (-0.50%)
After-hours: Jul 8, 2025, 4:11 PM EDT
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $150.17 million as of July 8, 2025. Its market cap has increased by 1,355.26% in one year.
Market Cap
150.17M
Enterprise Value
56.32M
1-Year Change
1,355.26%
Ranking
Category
Stock Price
$2.02
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $150.17M, an increase of 49.49%. That is a compound annual growth rate of 9.25%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 8, 2025 | 149.43M | -31.57% |
| Dec 31, 2024 | 218.38M | 2,684.93% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | 69.35M | -30.96% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 700.84B |
| Johnson & Johnson | 375.37B |
| AbbVie | 334.34B |
| Novo Nordisk | 316.33B |
| UnitedHealth Group | 279.90B |
| Novartis AG | 242.35B |
| Abbott Laboratories | 233.90B |
| AstraZeneca | 218.65B |